Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Interventions

• Atorvastatin Oral Tablet · DRUG

  Atorvastatin pill 40 mg to be taken every night

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:

* MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
* Memory, processing speed, executive function, language - cognitive scores \> 1.5 standard deviations below age-education norms.
* Not demented by history.
* Not taking statins currently or in the last 6 months.
* Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion Criteria:

* Taking a statin currently or have taken a statin in the last 6 months.
* Contraindications to taking a statin.
* Transplant patient taking cyclosporine.
* Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
* Diagnosis of dementia by history.
* Current diagnosis of substance abuse.
* History of stroke or myocardial infarction in past 6 months.
* History of HIV.

Sites (1)

• Johns Hopkins University, Bayview Medical Center, Baltimore, Maryland · RECRUITING